GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NAYA Biosciences Inc (NAS:NAYA) » Definitions » Net Income

NAYA (NAYA Biosciences) Net Income : $-7.47 Mil (TTM As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NAYA Biosciences Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. NAYA Biosciences's Net Income for the three months ended in Sep. 2024 was $-1.63 Mil. Its Net Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-7.47 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. NAYA Biosciences's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was $-5.03.


NAYA Biosciences Net Income Historical Data

The historical data trend for NAYA Biosciences's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NAYA Biosciences Net Income Chart

NAYA Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.17 -8.35 -6.66 -10.89 -8.04

NAYA Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.25 -2.00 -1.60 -2.25 -1.63

NAYA Biosciences Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

NAYA Biosciences's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-8.007+-0.028+0+0
=-8.04

NAYA Biosciences's Net Income for the quarter that ended in Sep. 2024 is calculated as

Net Income(Q: Sep. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=-1.601+-0.029+0+-0.0010000000000001
=-1.63

Net Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.47 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NAYA Biosciences  (NAS:NAYA) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

NAYA Biosciences's Earnings per Share (Diluted) (EPS) for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


NAYA Biosciences Net Income Related Terms

Thank you for viewing the detailed overview of NAYA Biosciences's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


NAYA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880